Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview

  title={Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview},
  author={Kishore V. L. Parsa and Manojit Pal},
  journal={Expert Opinion on Drug Discovery},
  pages={855 - 869}
Introduction: Alogliptin is a pyrimidinedione-based potent and selective inhibitor of DPP IV that was discovered by Syrrx (Takeda San Diego) for the treatment of type 2 diabetes mellitus (T2D). Alogliptin is currently launched in Japan with the results of its clinical trials indicating that it is generally well tolerated and shows relatively fewer adverse side effects than other existing therapies for T2D. Areas covered: The objective of the present review is to provide an overview of the… Expand
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Gemigliptin is a potent, long-acting, and highly selective DPP-4 inhibitor and can be a safe and effective drug for the long-term treatment of type 2 diabetes. Expand
Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.
The current review provides an overview of DPP4 and its inhibitors with emphasis on the structure, expression, activity, selectivity and pharmacokinetics information. Expand
Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors.
The design, synthesis and biological evaluation of spiro cyclohexane-1,2'-quinazoline scaffold hybridized with various heterocyclic ring systems through different atomic spacers as a highly potent DPP-4 inhibitors concluded that the target compounds could be highly beneficial for diabetic patients in the clinic. Expand
Novel DPP-4 inhibitors against diabetes.
The current landscape of the development of DPP-4 inhibitors is outlined in this review, with a focus on rational drug design and structural optimization to pursue chemical stability, selectivity and favorable pharmacokinetic properties. Expand
Effect of Alogliptin, a DPP-4 Inhibitor, on Markers of Lipid Metabolism in Type 2 Diabetic Patients
Administration of alogliptin in type 2 diabetic patients significantly improved levels of blood glucose, in addition to those of lipid metabolism markers such as LDL-C and non-fasting TG, as well as sensitive predictive markers for the onset risk of cardiovascular events, such as the Apo B/Apo A-1 ratio and the LDL-Apo B ratio. Expand
Long-acting peptidomimetics based DPP-IV inhibitors.
Pyrrolidine based peptidomimetics are reported as potent and selective DPP-IV inhibitors for the treatment of T2DM and the lead compound 16c showed sustained antihyperglycemic effects, along with improved pharmacokinetic profile. Expand
Design, synthesis, molecular simulation, and biological activities of novel quinazolinone-pyrimidine hybrid derivatives as dipeptidyl peptidase-4 inhibitors and anticancer agents
Twelve novel quinazolinone–pyrimidine hybrids were synthesized, of which some of them showed dual functions as DPP-4 inhibitors and anti-cancer agents.
Influence of the rs738409 polymorphism in patatin‐like phospholipase 3 on the treatment efficacy of non‐alcoholic fatty liver disease with type 2 diabetes mellitus
  • H. Kan, H. Hyogo, +12 authors K. Chayama
  • Biology, Medicine
  • Hepatology research : the official journal of the Japan Society of Hepatology
  • 2016
The efficacy of alogliptin is evaluated in NAFLD patients with type 2 DM as well as the relationship between genotypes at rs738409 in PNPLA3 and treatment efficacy. Expand
Ultrasound-based approach to spiro-2,3-dihydroquinazolin-4(1H)-ones: their in vitro evaluation against chorismate mutase
Amberlyst-15 has been identified as a green and reusable catalyst in the synthesis of spiro 2,3-dihydroquinazolin-4(1H)-ones under ultrasound irradiation at room temperature. The reaction can beExpand
A new route to indoles via in situ desilylation–Sonogashira strategy: identification of novel small molecules as potential anti-tuberculosis agents
A new Pd/C-mediated tandem reaction has been developed for the one pot synthesis of indoles containing an o-(RSO2NH)C6H4 group at the C-2 position. The methodology provided novel indoles asExpand


Alogliptin: a new addition to the class of DPP-4 inhibitors
Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. Expand
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Treatment of type 2 diabetes especially in the early stages of the disease via DPP-4 inhibition has been recognized as a validated principle and a large number of inhibitors are presently in various stage of pre-clinical/clinical development. Expand
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4) and related quinazolinone-based DPP-4 inhibitors provide sustained reduction of plasma D PP-4 activity and a lowering of blood glucose in animal models of diabetes. Expand
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Assessment of selectivity of potential clinical candidates may be important to an optimal safety profile for this new class of antihyperglycemic agents, according to the results of toxicity and tolerability studies. Expand
Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice
Treatment with a DPP-IV inhibitor can prolong islet graft retention in an animal model of type 1 diabetes, and PET imaging demonstrated a profound protective effect of MK0431 on is let graft size. Expand
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
The present review summarizes the latest preclinical and clinical trial data of different DPP IV inhibitors with a special emphasis on their DPP8/9 fold selectivity and therapeutic advantages over GLP-1 based approach. Expand
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
Sitagliptin has been shown to be effective and well-tolerated in various treatment regimens and may be considered for both initial therapy and as add-on therapy for patients with type 2 diabetes. Expand
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control
Alogliptin monotherapy was well tolerated and significantly improved glycemic control in patients with type 2 diabetes, without raising the incidence of hypoglycemia. Expand
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
The results suggest that DPPIV inhibition is a suitable approach for treatment of impaired glucose tolerance (IGT), and type 2 diabetes in the early stage, and the progression of insulin resistance appeared to block the improvement of glucose tolerance through DPPiv inhibition. Expand
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
  • C. Deacon
  • Medicine
  • Current opinion in investigational drugs
  • 2008
Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, TakedaExpand